MA25847A1 - Composition pour le traitement du dysfonctionnement endothelial. - Google Patents

Composition pour le traitement du dysfonctionnement endothelial.

Info

Publication number
MA25847A1
MA25847A1 MA27124A MA27124A MA25847A1 MA 25847 A1 MA25847 A1 MA 25847A1 MA 27124 A MA27124 A MA 27124A MA 27124 A MA27124 A MA 27124A MA 25847 A1 MA25847 A1 MA 25847A1
Authority
MA
Morocco
Prior art keywords
treatment
composition
endothelial dysfunction
dysfunction
endothelial
Prior art date
Application number
MA27124A
Other languages
English (en)
Inventor
Gerald Watts
David Playford
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR1038A external-priority patent/AUPR103800A0/en
Priority claimed from AUPR3424A external-priority patent/AUPR342401A0/en
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Publication of MA25847A1 publication Critical patent/MA25847A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA27124A 2000-10-26 2003-04-25 Composition pour le traitement du dysfonctionnement endothelial. MA25847A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR1038A AUPR103800A0 (en) 2000-10-26 2000-10-26 Compositions for the treatment of endothelial dysfunction
AUPR3424A AUPR342401A0 (en) 2001-02-28 2001-02-28 Compositions for the treatment of endothelial dysfunction

Publications (1)

Publication Number Publication Date
MA25847A1 true MA25847A1 (fr) 2003-07-01

Family

ID=25646491

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27124A MA25847A1 (fr) 2000-10-26 2003-04-25 Composition pour le traitement du dysfonctionnement endothelial.

Country Status (29)

Country Link
US (1) US7410983B2 (fr)
EP (1) EP1328266B1 (fr)
JP (1) JP4236464B2 (fr)
KR (1) KR100862129B1 (fr)
CN (1) CN1220488C (fr)
AR (1) AR035071A1 (fr)
AT (1) ATE316787T1 (fr)
AU (1) AU2176502A (fr)
BG (1) BG65979B1 (fr)
BR (1) BR0114701A (fr)
CA (1) CA2426625C (fr)
CY (1) CY1105007T1 (fr)
CZ (1) CZ301282B6 (fr)
DE (1) DE60117046T2 (fr)
DK (1) DK1328266T3 (fr)
DZ (1) DZ3442A1 (fr)
EE (1) EE05281B1 (fr)
ES (1) ES2257457T3 (fr)
HU (1) HUP0303566A3 (fr)
IL (2) IL155524A0 (fr)
MA (1) MA25847A1 (fr)
MX (1) MXPA03003733A (fr)
NO (1) NO332260B1 (fr)
PL (1) PL212952B1 (fr)
PT (1) PT1328266E (fr)
RU (1) RU2003111175A (fr)
SK (1) SK287992B6 (fr)
TN (1) TNSN01151A1 (fr)
WO (1) WO2002034259A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003005999A2 (fr) 2001-07-11 2003-01-23 Boehringer Ingelheim Pharmaceuticals, Inc. Methodes permettant de traiter des maladies induites par les cytokines
CA2481371A1 (fr) * 2002-03-11 2003-09-18 Peter Zahradka Utilisation d'agonistes de ppar alpha dans le traitement de maladies vasculaires et renales
US20070225614A1 (en) * 2004-05-26 2007-09-27 Endothelix, Inc. Method and apparatus for determining vascular health conditions
FR2845602B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
GB0309154D0 (en) * 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
FR2868313B1 (fr) * 2004-03-31 2008-08-15 Servier Lab Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
EP1621200A1 (fr) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Combinaison pharmaceutique comprenant un inhibiteur de l'aggregation des thrombocytes et un fibrate
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
SI1933821T1 (sl) 2005-09-15 2020-11-30 Ptc Therapeutics, Inc. Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev
EP1785133A1 (fr) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Utilisation du fenofibrate ou d'un de ses dérivés pour la prevention de la retinopathie diabetique
WO2007100652A2 (fr) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Variants à chaînes latérales d'agents thérapeutiques ayant une activité oxydoréductrice pour le traitement de maladies mitochondriales et d'autres conditions et pour la modulation de biomarqueurs énergétiques
US7897326B2 (en) 2006-03-16 2011-03-01 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Peroxisome-proliferator activated receptor-alpha agonists for organ preservation
US20070225606A1 (en) * 2006-03-22 2007-09-27 Endothelix, Inc. Method and apparatus for comprehensive assessment of vascular health
US20080027330A1 (en) * 2006-05-15 2008-01-31 Endothelix, Inc. Risk assessment method for acute cardiovascular events
US20080081963A1 (en) * 2006-09-29 2008-04-03 Endothelix, Inc. Methods and Apparatus for Profiling Cardiovascular Vulnerability to Mental Stress
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
WO2010088378A1 (fr) * 2009-01-29 2010-08-05 Levine Joshua D Procédé d'ajout d'agents botaniques/de suppléments de régime à des agents pharmaceutiques dans un régime pharmacothérapeutique
US8973851B2 (en) 2009-07-01 2015-03-10 The Procter & Gamble Company Apparatus and methods for producing charged fluid droplets
EP2551255B1 (fr) * 2010-03-26 2017-11-08 Vivacell Biotechnology España, S.L Dérivés quinone de cannabinoïdes
RU2554500C2 (ru) * 2013-09-20 2015-06-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ лечения ишемического инсульта
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2019084540A1 (fr) 2017-10-27 2019-05-02 Zeta Biolongevity, Inc. Compositions et méthodes pour traiter et prévenir la protéinurie et l'érosion endothéliale
CN110907407B (zh) * 2019-12-03 2022-02-25 东北石油大学 一种基于spr的高灵敏度光子准晶体光纤折射率传感器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229385A (en) 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FI102273B (fi) 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
FR2730231B1 (fr) 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
WO1997028149A1 (fr) * 1996-02-02 1997-08-07 Merck & Co., Inc. Procede pour augmenter les niveaux de cholesterol hdl
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
HUP0400931A2 (hu) 1997-11-28 2004-07-28 Karsanov, Nyikolai Vaszilievics Hypoxia és ischaemia elleni gyógyszer
WO2001015593A2 (fr) * 1999-09-02 2001-03-08 Drake Larson Compositions de reduction de formation de la plaque vasculaire et procedes d'utilisation associes

Also Published As

Publication number Publication date
HUP0303566A3 (en) 2005-05-30
JP4236464B2 (ja) 2009-03-11
EP1328266A1 (fr) 2003-07-23
BR0114701A (pt) 2003-11-18
MXPA03003733A (es) 2004-10-15
EE05281B1 (et) 2010-04-15
US20040022778A1 (en) 2004-02-05
DE60117046D1 (de) 2006-04-13
HK1057340A1 (en) 2004-04-02
KR100862129B1 (ko) 2008-10-09
EP1328266B1 (fr) 2006-02-01
PL361635A1 (en) 2004-10-04
KR20030055276A (ko) 2003-07-02
IL155524A0 (en) 2003-11-23
JP2004512302A (ja) 2004-04-22
CY1105007T1 (el) 2009-11-04
DE60117046T2 (de) 2006-09-28
ES2257457T3 (es) 2006-08-01
IL155524A (en) 2008-08-07
RU2003111175A (ru) 2004-09-10
SK287992B6 (sk) 2012-09-03
WO2002034259A1 (fr) 2002-05-02
PT1328266E (pt) 2006-05-31
NO20031851L (no) 2003-06-24
NO332260B1 (no) 2012-08-13
CA2426625C (fr) 2010-06-01
BG65979B1 (bg) 2010-08-31
AU2176502A (en) 2002-05-06
ATE316787T1 (de) 2006-02-15
DK1328266T3 (da) 2006-06-06
EE200300165A (et) 2003-06-16
AR035071A1 (es) 2004-04-14
DZ3442A1 (fr) 2002-05-02
CA2426625A1 (fr) 2002-05-02
CN1471390A (zh) 2004-01-28
SK5082003A3 (en) 2003-11-04
US7410983B2 (en) 2008-08-12
CN1220488C (zh) 2005-09-28
HUP0303566A2 (hu) 2004-03-01
PL212952B1 (pl) 2012-12-31
NO20031851D0 (no) 2003-04-24
TNSN01151A1 (en) 2005-11-10
CZ301282B6 (cs) 2009-12-30
BG107765A (bg) 2004-02-27

Similar Documents

Publication Publication Date Title
MA25847A1 (fr) Composition pour le traitement du dysfonctionnement endothelial.
MA25823A1 (fr) Compositions pour le traitement de l'eau.
MA26207A1 (fr) Compositions de traitement de l'eau.
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
EP1831385A4 (fr) Enzymes pour le traitement d'amidon
EP1536804A4 (fr) Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae
MA29098B1 (fr) Compositions pour le traitement du vhc
EP1534074A4 (fr) Polytherapie pour le traitement de l'obesite
EP1838321A4 (fr) Antagonistes de cxcr4 pour le traitement de l'infection due au vih
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EP1319401A4 (fr) Compositions pour reguler le desir de fumer
ATE276262T1 (de) Oxazinochinolone für die behandlung viraler infektionen
EP1359885A4 (fr) Inhibiteurs de nos pour le traitement des rides
EP1750513A4 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
MA25386A1 (fr) Formulation a delivrance controlee pour le traitement des copd
DK1326628T3 (da) Kemokinmutanter til behandling af dissemineret sklerose
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
EP1315503A4 (fr) Traitement contre le dysfonctionnement urinaire
EP1231840A4 (fr) Agent cellulaire anti-angiogenique destine au traitement du cancer
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
EP1161255A4 (fr) Procedes et compositions pour le traitement de la dyserection
EP1172113A4 (fr) Remedes pour le traitement des neuropathies automatiques
DK1268482T3 (da) Pyranoindoler til behandling af glaukom